Alnylam Pharmaceuticals this week said that the US Patent and Trademark Office has issued a notice of allowance for one of the company's patent applications related to lipid nanoparticles for systemic RNAi drug delivery.

Alnylam said that the patent application, No. 20100324120, is entitled “Lipid Formulation.” Alnylam said that it covers a variety of second-generation lipid nanoparticles including the so-called MC3 lipids used in the company's transthyretin-mediated amyloidosis drug ALN-TTR02 and its hypercholesterolemia treatment ALN-PCS.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.